Texas Risperdal Trial Ends When Janssen Settles For $158 Million, Company Says

AUSTIN, Texas -- Johnson & Johnson subsidiary Janssen LLP said Jan. 19 that it has agreed to pay $158 million to settle claims by Texas that it defrauded the Medicaid program through its off-label promotion of the atypical antipsychotic drug Risperdal ( State of Texas, ex rel. Allen Jones v. Janssen...